PMID-sentid Pub_year Sent_text comp_official_name comp_offsetprotein_name organism prot_offset 25499431-3 2015 These studies show that donepezil is a weak inhibitor of CYP3A4 (IC50=54.68+-1.00muM) whereas the reference agent ketoconazole exhibited potent inhibition (CYP3A4 IC50=0.20+-0.01muM). Donepezil 24-33 cytochrome P450 family 3 subfamily A member 4 Homo sapiens 156-162 32276526-8 2020 Risperidone commonly caused (85.7%) potential DDIs with donepezil, lamotrigine and trazodone via the CYP3A4 isoform. Donepezil 56-65 cytochrome P450 family 3 subfamily A member 4 Homo sapiens 101-107 26952092-1 2016 PURPOSE: The purpose of the study is to evaluate whether donepezil (D) plasma concentrations and activity of CYP2D6 and CYP3A4 are associated with the therapeutic response of patients with mild to moderate Alzheimer"s disease (AD). Donepezil 57-66 cytochrome P450 family 3 subfamily A member 4 Homo sapiens 120-126 25499431-3 2015 These studies show that donepezil is a weak inhibitor of CYP3A4 (IC50=54.68+-1.00muM) whereas the reference agent ketoconazole exhibited potent inhibition (CYP3A4 IC50=0.20+-0.01muM). Donepezil 24-33 cytochrome P450 family 3 subfamily A member 4 Homo sapiens 57-63 25499431-0 2015 Investigating the binding interactions of the anti-Alzheimer"s drug donepezil with CYP3A4 and P-glycoprotein. Donepezil 68-77 cytochrome P450 family 3 subfamily A member 4 Homo sapiens 83-89 25499431-5 2015 At higher concentrations, donepezil exhibited significant inhibition of CYP3A4 (69%, 84% and 87% inhibition at 100, 250 and 500muM, respectively). Donepezil 26-35 cytochrome P450 family 3 subfamily A member 4 Homo sapiens 72-78 25499431-1 2015 The anti-Alzheimer"s agent donepezil is known to bind to the hepatic enzyme CYP3A4, but its relationship with the efflux transporter P-glycoprotein (P-gp) is not as well elucidated. Donepezil 27-36 cytochrome P450 family 3 subfamily A member 4 Homo sapiens 76-82 25499431-8 2015 The molecular docking studies show that the 5,6-dimethoxyindan-1-one moiety of donepezil was oriented closer to the heme center in CYP3A4 whereas in the P-gp binding site, the protonated benzylpiperidine pharmacophore of donepezil played a major role in its binding ability. Donepezil 79-88 cytochrome P450 family 3 subfamily A member 4 Homo sapiens 131-137 25499431-2 2015 We conducted in vitro inhibition studies of donepezil using human recombinant CYP3A4 and P-gp. Donepezil 44-53 cytochrome P450 family 3 subfamily A member 4 Homo sapiens 78-84 25499431-9 2015 Energy parameters indicate that donepezil complex with both CYP3A4 and P-gp was less stable (CDOCKER energies=-15.05 and -4.91kcal/mol, respectively) compared to the ketoconazole-CYP3A4 and P-gp complex (CDOCKER energies=-41.89 and -20.03kcal/mol, respectively). Donepezil 32-41 cytochrome P450 family 3 subfamily A member 4 Homo sapiens 60-66 25499431-9 2015 Energy parameters indicate that donepezil complex with both CYP3A4 and P-gp was less stable (CDOCKER energies=-15.05 and -4.91kcal/mol, respectively) compared to the ketoconazole-CYP3A4 and P-gp complex (CDOCKER energies=-41.89 and -20.03kcal/mol, respectively). Donepezil 32-41 cytochrome P450 family 3 subfamily A member 4 Homo sapiens 179-185 23408070-6 2013 It has a t(1/2) of 6-8 h. Donepezil and galantamine are mainly metabolised by cytochrome P450 (CYP) 2D6 and CYP3A4 in the liver. Donepezil 26-35 cytochrome P450 family 3 subfamily A member 4 Homo sapiens 108-114 24433464-0 2014 Population pharmacokinetic approach to evaluate the effect of CYP2D6, CYP3A, ABCB1, POR and NR1I2 genotypes on donepezil clearance. Donepezil 111-120 cytochrome P450 family 3 subfamily A member 4 Homo sapiens 70-75 24107805-1 2014 AIM: The impact of CYP2D6 and CYP3A4 polymorphism on the steady-state plasma concentrations and therapeutic outcome of donepezil monotherapy and combination therapy in Alzheimer"s disease (AD) patients. Donepezil 119-128 cytochrome P450 family 3 subfamily A member 4 Homo sapiens 30-36 20931330-0 2011 Do CYP3A and ABCB1 genotypes influence the plasma concentration and clinical outcome of donepezil treatment? Donepezil 88-97 cytochrome P450 family 3 subfamily A member 4 Homo sapiens 3-8 22372724-2 2012 Donepezil is metabolized by the cytochrome P450 isozyme 3A4 (CYP3A4). Donepezil 0-9 cytochrome P450 family 3 subfamily A member 4 Homo sapiens 32-59 22372724-2 2012 Donepezil is metabolized by the cytochrome P450 isozyme 3A4 (CYP3A4). Donepezil 0-9 cytochrome P450 family 3 subfamily A member 4 Homo sapiens 61-67 20931330-1 2011 PURPOSE: The aim of our study was to evaluate the impact of CYP3A4, CYP3A5, and ABCB1 polymorphisms on donepezil disposition and clinical outcome. Donepezil 103-112 cytochrome P450 family 3 subfamily A member 4 Homo sapiens 60-66 12162759-7 2002 Tacrine is metabolised by hepatic cytochrome P450 (CYP) 1A2, and donepezil and galantamine are metabolised by CYP3A4 and CYP2D6. Donepezil 65-74 cytochrome P450 family 3 subfamily A member 4 Homo sapiens 110-116 19300564-7 2007 Donepezil is metabolized via CYP-related enzymes, especially CYP2D6, CYP3A4, and CYP1A2. Donepezil 0-9 cytochrome P450 family 3 subfamily A member 4 Homo sapiens 69-75 17908053-5 2007 Some cholinesterase inhibitors (tacrine, donepezil, galantamine) are metabolized via CYP-related enzymes, especially CYP2D6, CYP3A4, and CYP1A2. Donepezil 41-50 cytochrome P450 family 3 subfamily A member 4 Homo sapiens 125-131 9839763-10 1998 These observed changes, which are smaller than those produced by ketoconazole for other agents sharing the CYP-3A4 pathway, are most likely the result of donepezil also being metabolized by CYP-2D6, as well as its slow rate of clearance from plasma. Donepezil 154-163 cytochrome P450 family 3 subfamily A member 4 Homo sapiens 107-114